Great — here’s a compact, source-backed market snapshot for the RSV (respiratory syncytial virus) vaccine market with company references and the public numeric values I could verify. I list the most defensible numbers first, then short sections for Recent developments, Drivers, Restraints, Regional split, Emerging trends, Use cases, Challenges, Opportunities and Key expansion factors. I cite the key sources for the load-bearing facts so you can paste them into slides or a report.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global RSV Vaccine market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in RSV Vaccine market.

Read complete report at: https://www.thebrainyinsights.com/report/rsv-vaccine-market-14762

Headline market estimates (vendor variation — always state vendor & scope)

• Global RSV vaccines market USD 3.51 billion (2024); projected to reach USD 28.39 billion by 2030 (high CAGR; broad market scope). 

• Market USD 1.60 billion (2024); projected to reach USD 2.49 billion by 2032 (different methodology / narrower scope).

• Market USD 1,472.7 million (2024), with scenario analyses that show near-term declines in some forecasts depending on uptake/ recommendations.

Company reference table (concise — verified public values)

• GSK — Arexvy (older adults RSV vaccine)

  • 2024 sales: reported £590 million (Arexvy FY2024 sales reported in GSK materials; Q3 commentary noted substantial year-on-year declines vs launch year).

• Pfizer — Abrysvo (pregnancy + older adults indications)

  • 2024 sales: market reporting / company disclosures show ~US$755–890 million for Abrysvo in 2024 (different sources report $755M or $890M for full-year 2024/2023 depending on vendor basis); Pfizer also reported a 62% drop in Abrysvo sales in Q4 2024 vs Q4 2023 and gave quarterly/annual figures in its filings.

• Moderna — mRESVIA / mRNA RSV candidate

  • 2024 sales: very small initial commercial sales reported in recent vendor summaries (~US$25M in early commercial quarters, per RootsAnalysis) following regulatory approvals/rollouts. Moderna continues to expand indications and presentations.

• Market context (competition & shares): 2023–2024 commercial launches gave GSK market leadership in early sales, Pfizer and Moderna brought complementary labels/indications — but uptake has been volatile after guideline changes and seasonal variations. (See the recent reporting on sales declines and guideline impacts.) 

Recent developments (2023–2025)

• Multiple first-in-class approvals and commercial launches (2023–2024): GSK and Pfizer completed launches for older-adult and/or maternal indications; Moderna’s mRNA RSV program moved rapidly into approvals and early commercialization. These launches created the first commercial RSV vaccine market after decades.

• Rapid post-launch volatility: US guidance narrowing/prioritization and seasonal demand fluctuations led to sharp year-on-year declines in uptake and sales for Arexvy and Abrysvo in 2024 (companies reported big Q3/Q4 drops).

• IP / legal movement: notable patent disputes between GSK and Pfizer were dismissed/resolved in 2025 (affects competitive dynamics/prosecution risk).

Key drivers

• Large unmet burden of RSV disease in infants and older adults (hospitalizations / healthcare costs) — creates public-health and payer demand.

• Multiple approved vaccines with complementary labels (older adults, maternal immunization to protect infants) expand addressable market.

• Public health prioritization and seasonal programmatic vaccination (when public authorities adopt/endorse vaccination programmes, uptake rises sharply).

Main restraints

• Guideline & recommendation uncertainty (e.g., ACIP/CDC narrowing eligibility or prioritization reduces doses administered and pressures sales).

• Vaccine hesitancy & seasonal variability — if seasons are mild or public attention low, uptake falls.

• Pricing / procurement complexity in different markets and possible payer constraints for routine adult vaccination programs.

Regional segmentation (high level)

• North America (US): early and highest-value market for adult RSV vaccines (large public/private payer market; CDC/ACIP recommendations strongly shape demand).

• Europe: varied by country; some national recommendations (e.g., Germany) supported early uptake while others take a cautious approach.

• Asia-Pacific / Rest of World: high potential (large birth cohorts and older populations), but rollouts depend on national immunization policy decisions and supply agreements.

Emerging trends

• Maternal immunization programs (vaccinating pregnant people to protect infants) — expands infant protection without direct neonatal vaccination.

• Next-generation products & modalities: monoclonal prophylactics (extended half-life monoclonal antibodies for infants), mRNA & protein subunit improvements, and combination vaccines (RSV + influenza) under development.

• Shift toward targeted recommendations (risk-based vaccination) rather than universal adult programs in some markets — alters volume profiles.

Top use cases

1. Older adults vaccination (preventing severe RSV disease, hospitalizations).

2. Maternal immunization to protect infants in first months of life.

3. High-risk groups & institutional settings (long-term care facilities, immunocompromised patients).

Major challenges

• Demand uncertainty driven by public guidance — procurement and forecasting become harder for manufacturers and payers.

• Revenue volatility & launch economics — early blockbuster expectations tempered by rapid uptake swings (companies and analysts revised expectations).

• Competition across modalities (vaccines vs long-acting monoclonals for infants) — may fragment market share and pricing dynamics.

Attractive opportunities

• Maternal programs and infant protection (large birth cohorts in APAC & LATAM offer long-term growth).

• Combination vaccines & annualized adult programs (e.g., bundling RSV with influenza or other adult immunizations).

• Emerging markets & procurement deals — tiered pricing and Gavi/WHO engagement could unlock significant volume over time.

Key factors for market expansion

• Clear, favorable national immunization recommendations and inclusion in public programs.

• Manufacturers’ ability to manage supply, pricing and distribution to support seasonal campaigns.

• Clinical data & safety profile reassurance across ages (that maintain public and clinician confidence).